Attention Turns to Merck and AstraZeneca After Courts’ 340B Contract Pharmacy Rulings

The timing of the government’s forthcoming decision on the legality of Merck’s 340B contract pharmacy policy, and the grounds for its decision, are two big questions hovering over the 340B program.

The smoke is still clearing from three federal district judges’ recent decisions in drug manufacturers Lilly, Sanofi, Novo Nordisk, Novartis, and United Therapeutics’ 340B contract pharmacy lawsuits. In the rulings’ wake, we are keeping close tabs on what happens next

Read More »

Hospitals, Drug Manufacturers, and Lawyers Give their Takes on 340B Contract Pharmacy Rulings

A hospital group, drug manufacturers, and health care lawyers gave 340B Report their views on recent court rulings in five 340B contract pharmacy lawsuits.

A hospital group says two federal district judges got it right, but one got it wrong, on whether drug manufacturers are legally bound to provide 340B drug discounts for drugs dispensed at contract pharmacies.

In a Nov. 6 statement, 340B

Read More »

Breaking News

Breaking: Another Federal Judge Issues a Mixed Opinion in 340B Contract Pharmacy Litigation, this Time in Novartis and United Therapeutics’ Cases

U.S. District Judge Dabney Friedrich last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies.

A federal district judge last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies. Like the day’s earlier ruling, this one too was mixed,

Read More »

Breaking News

Breaking: Federal Judge Hands Down Mixed Opinion in Sanofi and Novo Nordisk’s 340B Contract Pharmacy Lawsuits

U.S. Chief District Judge Freda Wolfson ruled today that Sanofi and Novo Nordisk's 340B contract pharmacy policies violate the 340B statute. But she declined to decide whether the 340B statute permits covered entities to use multiple or unlimited contract pharmacies.

A federal district judge this afternoon upheld the federal government’s finding that drug manufacturers Sanofi and Novo Nordisk cannot unilaterally impose restrictions on offers of 340B pricing to covered entities and that their policies must cease.

U.S. Chief District Judge

Read More »

Feds Ask Judges to Follow Judge in Lilly Case and Validate HRSA’s Take on 340B Contract Pharmacy

DOJ has asked judges in five manufacturers' 340B contract pharmacy cases to follow to follow the lead of the judge in Lilly’s case and hold that these five companies’ contract pharmacy policies are illegal.

The federal government on Tuesday urged the judges in AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ separate 340B contract pharmacy lawsuits to follow the lead of the judge in Lilly’s case and hold that these five companies’ contract pharmacy

Read More »

Biden Taps Judge in AstraZeneca’s 340B Lawsuit for Appeals Court Seat

Leonard Stark, the federal district judge assigned to AstraZeneca’s 340B contract pharmacy lawsuit, was nominated yesterday to fill a vacancy on a federal appeals court in Washington, D.C.

President Biden yesterday nominated the federal district judge assigned to AstraZeneca’s 340B contract pharmacy lawsuit to fill a vacancy on a federal appeals court in Washington, D.C.

The White House announced U.S. District Judge Leonard Stark’s nomination to be a

Read More »

Limited Medicare Drug Price Negotiation Placed into Reconciliation Bill; 340B Impact Unclear

U.S. Senate Majority Leader Chuck Schumer (D-N.Y.) announced on Tuesday that congressional Democrats and the White House reached agreement on federal drug pricing legislation. | C-SPAN

Democratic lawmakers have come to an agreement for placing a limited drug price negotiation plan for the Medicare program into the Build Back Better bill, but how it will impact the 340B program remains to be seen.

“By empowering Medicare

Read More »

News Alert: CMS Will Continue Deep Cut in 340B Hospitals’ Medicare Part B Drug Reimbursement

CMS in 2022 will continue a nearly 30% reduction in place since 2018 in Medicare Part B reimbursement for many hospitals’ 340B-purchased drugs and biologicals.

In a big disappointment for 340B hospital organizations, the U.S. Centers for Medicare & Medicaid Services (CMS) announced late this afternoon that it will continue a nearly 30% reduction in place since 2018 in Medicare Part B reimbursement for hospitals’

Read More »

340B Stakeholders Size Up Friday’s Mixed Decision in Lilly’s 340B Contract Pharmacy Lawsuit

Both sides are claiming victory after Federal Judge Sarah Evans Barker’s ruling Friday in Eli Lilly’s lawsuit against HHS and HRSA.

Both sides are claiming victory after a federal judge’s ruling Friday in Eli Lilly’s lawsuit against federal health agencies in defense of its policies on 340B pricing when covered entities use contract pharmacies.

U.S. Senior Judge’s Sarah Evans Barker

Read More »

CMS Decision on Whether to Keep Part B Drug Payment Cuts for 340B Hospitals Could Come as Soon as Today

CMS could disclose as soon as today whether it will continue, end, or modify its nearly 30% cut in certain hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.

The U.S. Centers for Medicare & Medicaid Services (CMS) could disclose as soon as today whether it will continue, end, or modify the nearly 30% cut in certain hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.

The White House Office

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live